NanoRibo
Latest round
- Series A
Last raised
- Feb 2025
Total raised
- Undisclosed
Investors
- 2
About NanoRibo
, Ltd, dba NanoRibo, focuses on innovative RNA therapeutics aimed at enhancing immune responses against cancers. The firm specializes in advanced immunotherapy solutions that leverage RNA-based technologies to enhance therapeutic efficacy in cancer treatment. The company's core product offerings focus on novel RNA therapeutics aimed at modulating immune responses to target malignancies more effectively. These innovative therapies are designed to activate the immune system, recognizing and destroying cancer cells while sparing healthy tissue. The revenue structure of NanoRibo is primarily founded on B2B partnerships with healthcare providers and research institutions, facilitating the distribution and application of its RNA-based therapies. Transactions typically involve direct sales agreements, where healthcare facilities purchase therapeutic products for clinical use., a portfolio company of Yingke Private Equity, agreed to fully acquire NanoRibo.
Who invested in NanoRibo
2 investors across 1 round
See all investors in NanoRibo
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Feb 10, 2025
Amount
Undisclosed
Investors
Questions about NanoRibo
Who invested in NanoRibo?
NanoRibo has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has NanoRibo raised?
NanoRibo has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did NanoRibo last raise money?
NanoRibo's most recent round on record is a Series A, in Feb 2025.
What does NanoRibo do?
, Ltd, dba NanoRibo, focuses on innovative RNA therapeutics aimed at enhancing immune responses against cancers.
Where is NanoRibo headquartered?
NanoRibo is headquartered in Shanghai, China.
Which VCs invest in companies like NanoRibo?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at NanoRibo's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like NanoRibo? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.